GW841819X is a (+)-JQ1 analog and potent BET bromodomain inhibitor. It has demonstrated in vivo efficacy against NUT-midline carcinoma, multiple myeloma, and acute leukemias, supporting its use in oncology research targeting epigenetic regulation.